<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01667653</url>
  </required_header>
  <id_info>
    <org_study_id>11PDHD</org_study_id>
    <nct_id>NCT01667653</nct_id>
  </id_info>
  <brief_title>Probiotic Product in Healthy Adults Undergoing Antibiotic Treatment</brief_title>
  <official_title>A Randomized Parallel Group Study to Evaluate the Effect of a Probiotic Product in Healthy Adults Undergoing Antibiotic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danisco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KGK Science Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Danisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is randomized, double-blind, placebo controlled, single centre; 21 days phase II&#xD;
      clinical trial on healthy volunteers. Following baseline visit at the day of randomization,&#xD;
      treatment with Augmentin 875mg for 7 days will be given. Concurrently and after antibiotic&#xD;
      treatment subjects will also receive the study treatment, either probiotic or placebo. Daily&#xD;
      Bowel Habit Diary will be completed by the subjects. The subjects will be asked to collect&#xD;
      fecal samples for microbiological examination. The primary objective of the study is to&#xD;
      evaluate the maintenance of intestinal microbiota composition during antibiotic treatment&#xD;
      with Augmentin 875mg. Secondary objectives will be to evaluate the reduction in side effects&#xD;
      associated with antibiotic use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maintenance of intestinal microbiotic composition before, during and after antibiotic treatment with Augmentin 875mg</measure>
    <time_frame>3 weeks</time_frame>
    <description>Fecal samples collected during the 3 week period and stored frozen until analyses. Bacterial DNA is extracted from the samples and the microbial composition is analysed by molecular methods such as quantitative PCR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The influence of probiotics on side effects associated with antibiotic use</measure>
    <time_frame>3-weeks</time_frame>
    <description>Questionaire is used to assess the tolerability of the probiotic supplementation, Bowel habit scores, adverse effects,</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Antibiotic Therapy</condition>
  <arm_group>
    <arm_group_label>Augmentin/Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided in double blinded fashion probiotic to take with antibiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Augmentin/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided in double blinded fashion placebo to take with antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Probiotic capsule once daily</description>
    <arm_group_label>Augmentin/Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule once daily</description>
    <arm_group_label>Augmentin/placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 18 to 50 years.&#xD;
&#xD;
          -  Healthy as determined by laboratory results, medical history and physical exam&#xD;
&#xD;
          -  Willing to give voluntary, written, informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, breastfeeding, or planning to become pregnant during the&#xD;
             course of the trial&#xD;
&#xD;
          -  Body mass index â‰¥ 30 kg/m2&#xD;
&#xD;
          -  Average number of formed bowel movements &gt; 3 per day or &lt; 3 per week&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Participation in a clinical research trial within 30 days prior to randomization&#xD;
&#xD;
          -  Use of antibiotics within 60 days prior to randomization.&#xD;
&#xD;
          -  Habitual use of pro- and/or prebiotic products.&#xD;
&#xD;
          -  Follows a vegetarian or vegan diet&#xD;
&#xD;
          -  Unstable medical conditions&#xD;
&#xD;
          -  Any evidence of acute or chronic gastrointestinal disorder&#xD;
&#xD;
          -  Alcohol use &gt; 2 standard alcoholic drinks per day and/or alcohol or drug abuse within&#xD;
             past year&#xD;
&#xD;
          -  Allergy or sensitivity to test product ingredients or antibiotic&#xD;
&#xD;
          -  Any other condition which in the Investigator's opinion may adversely affect the&#xD;
             subject's ability to complete the study or its measures or which may pose significant&#xD;
             risk to the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London/Ontario</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>March 23, 2012</study_first_submitted>
  <study_first_submitted_qc>August 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2012</study_first_posted>
  <last_update_submitted>August 14, 2012</last_update_submitted>
  <last_update_submitted_qc>August 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

